State Street
TARS icon

State Street’s Tarsus Pharmaceuticals TARS Stock Holding History

State Street’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5M Buy
1,072,951
+94,739
+10% +$6.05M ﹤0.01% 1692
2026
Q1 		$68.6M Buy
978,212
+49,153
+5% +$3.43M ﹤0.01% 1580
2025
Q4 		$76.1M Sell
929,059
-7,103
-0.8% -$530K ﹤0.01% 1502
2025
Q3 		$55.6M Sell
936,162
-44,706
-5% -$2.2M ﹤0.01% 1675
2025
Q2 		$39.7M Buy
980,868
+70,152
+8% +$3.16M ﹤0.01% 1802
2025
Q1 		$46.8M Sell
910,716
-6,140
-0.7% -$304K ﹤0.01% 1679
2024
Q4 		$50.8M Buy
916,856
+17,477
+2% +$794K ﹤0.01% 1710
2024
Q3 		$29.6M Sell
899,379
-26,260
-3% -$738K ﹤0.01% 1987
2024
Q2 		$25.2M Buy
925,639
+208,549
+29% +$7.01M ﹤0.01% 2055
2024
Q1 		$26.1M Buy
717,090
+42,259
+6% +$1.24M ﹤0.01% 2055
2023
Q4 		$13.7M Buy
674,831
+129,899
+24% +$2.17M ﹤0.01% 2416
2023
Q3 		$9.68M Buy
544,932
+124,216
+30% +$2.2M ﹤0.01% 2617
2023
Q2 		$7.6M Buy
420,716
+56,421
+15% +$897K ﹤0.01% 2790
2023
Q1 		$4.58M Buy
364,295
+17,635
+5% +$258K ﹤0.01% 3029
2022
Q4 		$5.08M Buy
346,660
+53,549
+18% +$886K ﹤0.01% 3036
2022
Q3 		$5.02M Buy
293,111
+56,595
+24% +$899K ﹤0.01% 3056
2022
Q2 		$3.45M Buy
236,516
+103,633
+78% +$1.56M ﹤0.01% 3277
2022
Q1 		$2.23M Buy
132,883
+3,141
+2% +$58.3K ﹤0.01% 3518
2021
Q4 		$2.92M Buy
129,742
+2,940
+2% +$76.4K ﹤0.01% 3502
2021
Q3 		$2.73M Buy
126,802
+7,661
+6% +$190K ﹤0.01% 3525
2021
Q2 		$3.45M Buy
119,141
+18,757
+19% +$586K ﹤0.01% 3405
2021
Q1 		$3.23M Buy
100,384
+3,500
+4% +$129K ﹤0.01% 3234
2020
Q4 		$4M Buy
+96,884
New +$2.76M ﹤0.01% 3069

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street's TARS Position: Q2 2026 in Review

State Street increased its Tarsus Pharmaceuticals (TARS) stake by 9.7% in Q2 2026, buying an estimated $6.05M and bringing the position to 1,072,951 shares worth $67.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

State Street first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $76.1M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • State Street held 1,072,951 shares of Tarsus Pharmaceuticals worth $67.5M as of Q2 2026.
  • State Street bought 94,739 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $6.05M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1692 holding.
  • State Street first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • State Street's Tarsus Pharmaceuticals position peaked at $76.1M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.